Results 151 to 160 of about 3,792 (182)

Long-term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva. [PDF]

Rheumatology (Oxford)
Haviv R, Zeitlin L, Moshe V, Ziv A, Rabinowicz N, De Benedetti F, Prencipe G, Matteo V, De Cunto CL, Hsiao EC, Uziel Y.   +10 more
europepmc   +1 more source

Intersections of Fibrodysplasia Ossificans Progressiva and Traumatic Heterotopic Ossification. [PDF]

Biomolecules
Juan C, Bancroft AC, Choi JH, Nunez JH, Pagani CA, Lin YS, Hsiao EC, Levi B.   +7 more
europepmc   +1 more source

Fibrodysplasia ossificans progressiva.

Indian pediatrics, 1988
K, Chopra, M M, Saha, S, Saluja
openaire   +1 more source

Cellular and Molecular Mechanisms of Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva. [PDF]

Biomedicines
Mejias Rivera L, Shore EM, Mourkioti F.
europepmc   +1 more source

Fibrodysplasia Ossificans Progressiva: A rare disease due to unawareness, case report and literature review. [PDF]

Int J Surg Case Rep
Guyolla YH, Abebe FT, Ahmed AJ.
europepmc   +1 more source

[¹⁸F]NaF PET/CT as a Marker for Fibrodysplasia Ossificans Progressiva: From Molecular Mechanisms to Clinical Applications in Bone Disorders. [PDF]

Biomolecules
Zwama J, Rosenberg NM, Verheij VA, Raijmakers PGHM, Yaqub M, Botman E, de Ruiter RD, Garrelfs MR, Bökenkamp A, Micha D, Schwarte LA, Teunissen BP, Lammertsma AA, Boellaard R, Eekhoff EMW.   +14 more
europepmc   +1 more source